loader
Please Wait
Applying Filters...

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Drug Master Files (DMF) for 23559 Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Arkema

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 Arkema (1)

    filter

    01 LUPEROX A75FP (1)

    filter

    01 France (1)

    filter

    01 Active (1)

    filter

    01 Complete (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    ARKEMA INC

    Contact Supplier
    • FDA
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    LUPEROX A75FP

    PDF Supplier PDF
    URL Supplier Web Content
    23559
    Active
    2010-02-12
    Complete
    2014-04-15
    2013-02-25
    II
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for Drug Master Files (DMF) for 23559 of Arkema Inc

    Looking for Drug Master Files (DMF) for 23559 of Arkema Inc 1

    20

    Arkema Inc, based in France, is a pharmaceutical company that stands out with its certifications from FDA.

    One of their notable products is LUPEROX A75FP, with a corresponding US DMF Number 23559.

    Remarkably, this DMF maintains an Active status since its submission on February 12, 2010, highlighting commitment to regulatory compliance.

    Their GDUFA DMF Review was successfully complete, with a review date of April 15, 2014, and payment made on February 25, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II

    Post Enquiry
    POST ENQUIRY